1Bellisarii FL, Gallina S, De Caterina R. Tumor nercosis factor- alpha and cardiovascular diseases. Ital Heart J, 2001, 2: 408- 417.
2Nishimura T, Vsazar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation, 2003, 108 : 1640- 1645.
3Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med, 2002, 166:1403-1408.
4] Murata T, Sato K, Hori M, et al. Decreased endothelial nitricoxide synthase(eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem, 2002, 277: 44085-44092.
5Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vase Biol, 2005, 25 : 2335- 2342.
6Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol, 2003, 285 : H938-945.
7Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol, 1994, 144:275- 285.
9Kinlay S. Potential vascular benefits of statins. Am J Med, 2005, 118(Suppl 12A) : 62-67.
10Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-imflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol, 2001, 21:115-121.
3Thirapatarapong W, Armstrong H F, Barrels M N. Exercise capacity and ventilatory response during exercise in COPD patients with and without β blockade[ J] .Lung, 2013, 191 (5) : 531-536.
4Brun H, Holmstrm H, Thaulow E, et al. Patients with pul- monary hypertension related to congenital systemic to pul- monary shunts are characterized by inflammation involving endothelial cell activation and platelet mediated inflamma- tion[ J].Congenital Heart Disease, 2009, 4(3) : 153-159.
5Wynants M, Quarck R, Ronisz A, et al. Effects of C-reac- tive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension [ J ], European Respiratory Journal, 2012, 40(4): 886-894.
7ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS statement:guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine . 2002
8Young RP,Hopkins RJ.Update on the potential role of statins in chronic obstructive pulmonary disesase and its co-morbidities. Expert Rev Respir Med . 2014
